Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Others

Ratios

Rocket Pharmaceuticals (RCKT) Asset Writedowns and Impairment (2017 - 2020)

Rocket Pharmaceuticals (RCKT) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with -$1000.0 as the latest value for Q2 2020.

Quarterly Asset Writedowns and Impairment changed N/A to -$1000.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was -$1000.0 through Dec 2023, down 101.61% year-over-year, with the annual reading at $262000.0 for FY2025, N/A changed from the prior year.
Asset Writedowns and Impairment hit -$1000.0 in Q2 2020 for Rocket Pharmaceuticals, down from $63000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $63000.0 in Q1 2020 to a low of -$1000.0 in Q2 2020.